(Alliance News) - Ulysses Biomed Spa announced Tuesday that Hyris Limited, a wholly owned subsidiary of UBM, has successfully concluded an international project to develop technology aimed at active surveillance of the spread of malaria in remote and disadvantaged countries.

The project lasted for three years starting in 2021 and was funded by the Bill and Melinda Gates Foundation for a total of USD1.5 million of which USD260,000 was earmarked for Hyris' technology development.

The research team was led by George Dimopoulos of the Johns Hopkins Bloomberg School of Public Health and the Johns Hopkins Malaria Research Institute, together with Professor Charles Wondji of the Infectious Disease Research Center in Yaoundé, Cameroon.

This new technological solution enables real-time surveillance of insecticide resistance in mosquitoes and other parameters that will help optimize disease control campaigns and anticipate outbreaks for better protection of endemic populations.

Ulysses Biomed's stock closed 0.7 percent in the red on Tuesday at EUR1.52 per share.

By Chiara Bruschi, Alliance News reporter

Comments and questions to redazione@alliancenews.com

Copyright 2024 Alliance News IS Italian Service Ltd. All rights reserved.